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Background
Prognosis in patients with heart failure (HF) has been improving over recent decades [1] , but the change has been heterogeneous. Between 1987 and 2001, survival improved over time for patients with reduced ejection fraction (HFrEF) but not for those with preserved ejection fraction (HFpEF) [2] .
One explanation could be that patients with HFpEF have specific characteristics (e.g. they are older, are more often women, and are more likely to have hypertension and atrial fibrillation than patients with HFrEF) [2] [3] [4] [5] , specific prognostic factors [2] [3] [4] 6] and specific responses to medication (evidence concerning the efficacy of conventional HF drugs in patients with HFpEF being poor [7] [8] [9] [10] [11] [12] [13] ). Accordingly, other paths of intervention should be explored to improve prognosis in HFpEF. For instance, patient education programmes (PEPs), which have been recommended for patients with HF since 2008 [14] , have not been specifically assessed in HFpEF. There is evidence of the efficacy and effectiveness of PEPs in HF. In 2002, a randomized controlled trial reported that a PEP reduced the readmission rate in patients with HF by 39% [15] . More recently, the Observatoire de l'insuffisance cardiaque (ODIN) cohort study highlighted the potential of a PEP to reduce allcause mortality in HF [16] . However, these studies included patients with HF in general, whatever their left ventricular ejection fraction (LVEF). To our knowledge, no study has addressed the question of the effectiveness of PEPs specifically in patients with HFpEF.
The aim of the present investigation was to assess the effectiveness of PEPs in reducing all-cause mortality in patients with HFpEF.
Methods
Setting, design and patients
The I-CARE project [17] , initiated in 2003, aimed to implement over time a standardized PEP for patients with chronic HF in more than 220 hospitals in France, Belgium and Luxembourg. The ODIN cohort, including patients with HF from hospitals enrolled in the I-CARE project whatever their LVEF, was set up in 2007 to assess the effectiveness of this programme on morbidity and mortality in France. Sixty-one French hospitals from centres involved in the I-CARE project volunteered to enrol patients with chronic HF, regardless of their participation in the PEP. The ODIN cohort has been described extensively elsewhere [16] .
This cohort study conforms to the principles outlined in the Declaration of Helsinki. All patients gave informed consent before their inclusion in the cohort. ODIN was registered on ClinicalTrials.gov website under the number NCT01091441.
Between July 2007 and July 2010, a total of 3237 patients with a diagnosis of HF established by a trained cardiologist were included in ODIN. Among them, 849 patients had HFpEF, defined as LVEF > 45%, and were included in the present investigation (Fig. 1) .
PEP
All patients received conventional care in accordance with the European guidelines for HF available at the time of ODIN [14] . Cardiologists proposed that patients participate in the I-CARE PEP; some agreed, others did not. Accordingly, the cohort was split into two groups: patients who did not participate in the PEP (the NO PEP group) and those who did (the PEP group), as defined below.
NO PEP patients received standard care. In addition to standard care, PEP patients also participated in a full structured PEP delivered by trained cardiologists, dieticians and nurses, described extensively elsewhere [16] . Briefly, the first PEP step consisted of an educational diagnosis (i.e. tailored educational objectives established on the basis of an accurate assessment of the patient's needs and skills). The second PEP step consisted of three to five education sessions, each lasting for 1-2 hours. Using I-CARE educational tools [18] during collective or individual sessions, health professionals addressed different topics, such as knowledge of the pathophysiology of HF, symptoms of worsening HF and how to monitor them, dietary recommendations, management of activities and exercise, practical considerations for daily living and medications. The last PEP step consisted of evaluating improvements in the patient's knowledge and skills. 
Baseline data collection
In each hospital, trained cardiologists used a standardized form to collect baseline patient characteristics. In addition to PEP group, social, demographic, clinical, behavioural and biological characteristics and treatments were recorded.
Social and demographic characteristics consisted of age, sex, relative availability (living alone or not), area of residence (urban, rural), type of residence (house, apartment or institution), educational level and limitations of activities of daily living. Clinical and behavioural characteristics included number of co-morbidities, duration of HF, number of HF hospitalizations in the year before inclusion, usual cardiovascular risk factors (body mass index, hypertension, diabetes mellitus, hypercholesterolaemia, current smoking and alcohol abuse), cause of HF, New York Heart Association (NYHA) class, presence of lower limb oedema in the previous 6 months and electrocardiographic characteristics (sinus rhythm, atrial fibrillation, left bundle branch block and paced heart rhythm). LVEF was also recorded.
Biological characteristics included fasting glucose, glomerular filtration rate estimated using the simplified equation from the Modification of Diet in Renal Disease (MDRD) trial [19] , haemoglobin and serum B-type natriuretic peptide (BNP) and/or N-terminal proB-type natriuretic peptide (NTproBNP). BNP and/or NTproBNP results were categorized in two groups: decompensated or non-decompensated BNP/NTproBNP status (non-decompensated was defined as BNP ≤ 400 pg/mL and NTproBNP ≤ 450 pg/mL for patients aged < 50 years, ≤ 900 pg/mL for patients aged 50-75 years and ≤ 1800 pg/mL for patients aged > 75 years [20] ).
Treatments covered prescriptions of HF medications (beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, loop diuretics, thiazides and digoxin), other cardiovascular medications (nitrates, calcium channel blockers, amiodarone, oral anticoagulants, aspirin, clopidogrel and statins) and non-pharmacological HF treatments (pacemaker, biventricular pacing, implantable cardioverterdefibrillator, coronary artery bypass graft and valve surgery).
Endpoint and follow-up
The endpoint was all-cause mortality, as collected from civil registries, medical records and telephone calls to general practitioners, cardiologists or relatives. Survival time was calculated from date of inclusion in the cohort, ranging from July 2007 to July 2010. Survivors were censored at the end of the follow-up period, set at 31 December 2013.
Statistical analyses
First, all baseline patient characteristics mentioned above were described according to PEP group. Categorical variables are reported as numbers and percentages, and quantitative variables as means ± standard deviations. Balance of characteristics was assessed by estimating standardized differences (StDiffs) between groups. StDiff indicates the degree of systematic differences in covariates between groups. Empirically, an StDiff > 10% represents meaningful imbalance in a given variable between groups [21] .
To assess the effect of PEP on all-cause mortality, a propensity score analysis was performed to take into account imbalances in baseline characteristics between the PEP and NO PEP groups [22] . Propensity scores were calculated using a logistic regression model based on a dependent variable (PEP versus NO PEP) and independent variables. Independent variables considered in the model were baseline patient characteristics with an absolute StDiff ≥ 10% between groups, in addition to baseline patient characteristics with an absolute StDiff < 10%, but known to be prognostic factors (i.e. education level, HF duration, number of co-morbidities, diabetes mellitus, valvular heart disease, paced rhythm, haemoglobin and treatment by angiotensin-converting enzyme inhibitors, nitrates, pacemaker or biventricular pacing). Continuous variables were entered as such in the model; log linearity was assessed first. Propensity score distribution was plotted in the two groups (PEP and NO PEP) to assess the overlap. Mean ± standard deviation, minimum and maximum propensity scores were described in the two groups.
A 1:1 propensity score matching without replacement was performed, using a calliper of 0.02. After matching, the balance of baseline patient characteristics was assessed by estimating StDiff between groups.
In paired samples, survival curves in the PEP versus NO PEP groups were generated by the Kaplan-Meier method. Crude associations between PEP and all-cause mortality were assessed using a shared frailty model based on Cox proportional hazards models appropriate for the analysis of matched data. Then, adjustment for post-match residual unbalanced characteristics was considered. Proportional hazard assumption was assessed using the Schoenfeld residual and was not violated. Results are reported as hazard ratios (HRs) and 95% confidence intervals (CIs). A P value of < 0.05 was considered statistically significant.
All variables with missing data were addressed with multiple-imputation methods [23] . All covariates were used to create five imputed data sets, using the Markov Chain Monte Carlo method and the Jeffreys prior for quantitative variables, and a fully conditional specification method for categorical variables. All steps of the analyses described above were conducted in the five imputed data sets, and results were pooled as shown in Fig. 1 .
All statistical analyses were performed with SAS ® software, version 9.3 (SAS Institute, Inc., Cary, NC, USA).
Reporting of the study conforms to the STROBE statement, along with references to STROBE and to the broader EQUA-TOR guidelines [24] .
Results
Patient characteristics
Of 849 HFpEF considered here, 572 (67.4%) patients participated in the PEP and 277 (32.6%) did not. Overall, the mean age was 71.1 ± 13.5 years and 361 (42.5%) patients were women. Mean LVEF was 58.1 ± 8.4%. The main cause of HF was ischaemia (35.8%), and 640 (81.8%) patients were in NYHA class I or II. Baseline patient characteristics according to PEP group are presented in Table 1 .
Compared with the NO PEP group, patients in the PEP group were younger (StDiff-54.6%), less often women (StDiff-17.6%), less limited in their activities of daily living (StDiff-37.1%), presented more often with hypercholesterolaemia (StDiff 41.2%). The main cause of HF in the PEP group was more often ischaemia (StDiff 20.0%), whereas hypertension was more often the main cause of HF in the NO PEP group (StDiff-19.0%). Patients in the PEP group had better cardiovascular conditions: HF was less severe (StDiff-39.2%), they had a lower prevalence of atrial fibrillation (StDiff-37.8%), a higher mean glomerular filtration rate (StDiff 34.7%) and more often presented with nondecompensated BNP/NTproBNP (StDiff 34.1%). In addition, those in the PEP group were more likely to receive HF medications (Table 1) .
Data were missing at random for 29 baseline variables. The proportions of missing data ranged from 1% to 39% (i.e. 14 baseline variables with missing values < 10%, six baseline variables with missing values ranging from 10-20%, five baseline variables with missing values ranging from 20-30% and four baseline variables with missing values ranging from 30-39%). The matching procedure generated five datasets, sample sizes of which ranged from 382 to 410 patients. After matching, baseline characteristics balanced overall (pooled variables shown in Table 1 ), except for hypertension (PEP 69.0% vs NO PEP 59.9%; StDiff 19.1%).
Propensity score matching
Follow-up
Overall, among the 849 patients, the median length of follow-up was 44.1 months, ranging from 0.0 to 75 months. During follow-up, 320 patients died (173 in the PEP group and 147 in the NO PEP group). The overall mortality rate was 49.9% at the end of follow-up.
The number of deaths ranged from 156 to 165 through the five data sets of matched patients (i.e. from 62 to 68 in the PEP group and from 93 to 97 in the NO PEP group). At the end of follow-up, pooled mortality rates were 45.0% in PEP patients and 56.9% in NO PEP patients.
Impact of PEP on all-cause mortality
Estimates of the effect of PEP on mortality in the matched datasets before and after pooling are reported in Table 2 . Kaplan − Meier estimates in each of the five matched datasets are presented in Fig. 2 .
PEP was associated with a lower mortality (Table 2 , model 1, pooled HR 0.70, 95% CI 0.49-0.99; P = 0.042). Further adjustment for hypertension because of residual imbalance after matching between groups did not modify this result (Table 2 , model 2, pooled HR 0.68, 95% CI 0.48-0.97; P = 0.036). 
Discussion
The present investigation assessed the effectiveness of a PEP on all-cause mortality in patients with HFpEF. After reduction of indication bias using propensity-score matching, the PEP was effective in reducing all-cause mortality. In our study, a 30% relative risk reduction was observed in patients with HFpEF participating in the PEP, which is substantial compared with the 9% relative risk reduction related to the use of beta-blockers in this population, as reported in a recent meta-analysis [9] . Moreover, to date, many medications have failed to improve prognosis in HFpEF. For instance, candesartan and irbesartan were not associated with a mortality reduction [10, 13] . Similarly, perindopril failed to demonstrate any effect on mortality in patients with HFpEF [8] , as well as digoxin [7] . In a more recent study, spironolactone did not significantly reduce cardiovascular mortality [12] . Accordingly, PEP should be helpful to improve survival in patients with HFpEF. In their trial, Krumholz et al. [15] reported a 30% relative risk reduction in a composite endpoint of readmissions or death for an intervention based on patient education in patients with HF aged 74 years and presenting with a mean LVEF of 37%. The intervention focused on patient knowledge of the illness and its relationship with medications and health behaviours, knowledge of early signs and symptoms of decompensation and the ways to obtain assistance [15] . The relative risk reduction in mortality that they found was similar to our result, but did not reach statistical significance (P = 0.33) [15] . A small number of events (nine deaths in the intervention group vs 13 in the control group) leading to a lack of power probably explained this non-significant result. Jaarsma et al. [25] conducted a randomized study to assess the effects of a disease management programme (based on support by a nurse, multidisciplinary advice sessions and home visits, in patients with HF) on a composite endpoint of readmission and deaths. Patient education was led by trained health professionals and addressed patient self-efficacy using a patient diary, brochures on HF and its management and samples of sodium-restricted food seasonings [25] . The mean age of the patients with HF was 71 years, and their mean LVEF was 34% [25] . Interestingly, the authors found no differences between groups in the main composite endpoint, but a 15% relative risk reduction for mortality, although this was not statistically significant [25] . As noted above, a small number of deaths (17 in the intervention groups vs nine in the control group) [25] occurring during the follow-up probably explain this non-significant result. With a PEP focused on quite similar domains to the one evaluated by Krumholz et al. [15] , and an investigation design leading to 320 deaths at the end of the follow-up, we found a similar yet significant relative risk reduction for mortality in patients with HFpEF aged 73 years and presenting with a mean LVEF of 58%. This 30% relative risk reduction for mortality in HFpEF was similar to the 27% relative risk reduction for mortality observed for the whole ODIN cohort, which included patients with HF with a mean age of 68 years, a mean LVEF of 40% and followed up for 2 years [16] .
Results concerning the duration of the effect of patient education on morbidity and mortality are conflicting to date. One could argue, based on the results of the SPAN-CHF study [26] or those of Ojeda et al. [27] , that patient education in HF is associated with improved short-term outcomes, but fails to provide long-term benefits. However, Galbreath et al. [28] showed that a disease management programme was effective in reducing mortality in a community-based sample of patients with HF after a median follow-up of 2 years. Although patient education is only part of disease management programmes, its long-term effectiveness on patient readmission in HF has been proven [29] . One could also argue that the number of sessions is crucial to observe an effect of patient education. Krumholz et al. [15] showed that five education sessions were associated with lower all-cause readmission or death and lower HF or other cardiovascular disease readmission or death. In our investigation, three to five patient education sessions were associated with lower long-term all-cause mortality.
In our sample, 40-45% of patients presented with an education level lower than elementary school, which might be associated with low health literacy, defined as significant difficulties with routine reading requirements, such as reading prescriptions, self-care instructions and health education brochures. Low health literacy is associated with impaired prognosis in patients with HF [30] . Receiving special instructions regarding medications, worsening symptoms that require a medical consultation, dietary recommendations, activities and exercise during three to five dedicated education sessions lasting for at least 1 hour might help to improve the prognosis in patients with special needs, through their better understanding of HF. The I-CARE PEP targeted behavioural factors, and used specific tools developed by trained cardiologists, dieticians and nurses during these education sessions. These tools are based on easy-to-understand pictures, with very few words, illustrating, for instance, how to monitor weight, what situations require medical consultation, what types of food should be favoured or avoided to control salt intake, how to achieve water restriction and what types of physical activities should be favoured and why [18] . Moreover, mixing collective and individual sessions might enhance the understanding of the education topic being addressed by sharing experiences in pairs during workshops driven by patient education specialists, and by tailoring education key messages during one-to-one teaching sessions. The strength of this PEP does not rely only on simple advice, but also on enhancing the will of the patients to follow the advice, and their ability to achieve tailored objectives.
Another issue regarding PEPs is how far they are actually implemented. Concerning the I-CARE PEP, a thorough process evaluation has been done to assess its implementation [17] . An educational diagnosis was made in 89.2% of the centres, and education was provided through collective workshops (73.0%) or one-to-one teaching sessions (75.7%). A complete education programme for a patient consisted of a median of four sessions (25th-75th percentile, two to five sessions) and lasted for a median of 6 hours (25th-75th percentile, 4-10 hours). The education team was multidisciplinary, and usually included a nurse (93.2%), a dietician (78.4%), a cardiologist (71.6%) and a physiotherapist (40.5%). HF educational tools were used, at least in part, in most centres (89.2%) [17] .
Given the purposes of PEPs, other endpoints, such as quality of life, autonomy or HF hospitalizations, should be considered to holistically assess their effectiveness. However, decreasing mortality might be the first milestone for a condition that results in mortality rates as high as 49.9% during a median follow-up of 44.1 months.
Study limitations
First, patients were not assigned randomly to groups. However, considering the European guidelines for disease management programmes including PEPs in patients with HF at the time of our study, randomization was impractical for ethical reasons [14] . Moreover, a propensity score matching procedure was used to reduce confusion bias caused by a baseline imbalance in patient characteristics between groups [31] . Propensity scores cannot remove hidden biases, except to the extent that unmeasured prognostic variables are correlated with the measured covariates used to compute the score [32] . Thus, residual bias remains possible in our study. However, all the well-known prognostic factors in HFpEF were collected in our study [2] [3] [4] 6] , preventing our results from a major risk of residual unmeasured confounding.
Second, our sample of patients with HFpEF might not be fully representative of the whole population of patients with HFpEF. The proportion of patients with HFpEF in ODIN (28.3%) was well below that observed in the general population. Indeed, patients with HFpEF account for about half of the patients with HF in the general population [33] . However, baseline HFpEF patient characteristics in ODIN were similar to those observed in patients with HFpEF recruited after hospital admission, for whom the mean age reported was 74 years [2, 5] , and the ischaemic cause of HF frequency lay between 17% [3] and 53% [2] , except for the proportion of women, which was slightly higher than those reported previously in patients with HFpEF [2] [3] [4] [5] . Accordingly, our results are expected to be of fair external validity.
Third, evaluating the effectiveness of the PEP in terms of specific cardiac mortality would have been interesting. However, cause of death was collected but not validated in ODIN at the time of our investigation, and the choice of all-cause mortality as the outcome is justified from a public health perspective (i.e. to reduce all-cause mortality).
Conclusion
In a large sample of patients with HFpEF, a PEP focused on pathophysiology and medication, symptoms of worsening HF, dietary recommendations and management of exercise was associated with a 30% relative risk reduction for all-cause mortality. Considering the paucity of evidence of HFrEF medication efficacy in patients with HFpEF so far, patient education might be considered an effective treatment in HFpEF.
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